PD-L1 ( CD274 ) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
Article
Klümper, Niklas, Wüst, Lennert, Saal, Jonas, Ralser, Damian J., Zarbl, Romina, Jarczyk, Jonas, Breyer, Johannes, Sikic, Danijel, Wullich, Bernd, Bolenz, Christian, Roghmann, Florian, Hölzel, Michael, Ritter, Manuel, Strieth, Sebastian, Hartmann, Arndt, Erben, Philipp, Wirtz, Ralph M., Landsberg, Jennifer, Dietrich, Dimo and Eckstein, Markus (2023) PD-L1 ( CD274 ) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. OncoImmunology 12 (1).Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | OncoImmunology | ||||
| Publisher | TAYLOR & FRANCIS INC | ||||
| Place of Publication | PHILADELPHIA | ||||
| Volume | 12 | ||||
| Number of Issue or Book Chapter | 1 | ||||
| Date | 2023 | ||||
| Date of publication | 18 Mar 2025 10:11 | ||||
| Institutions | Medicine > Lehrstuhl für Urologie | ||||
| Identification Number |
| ||||
| Keywords | CISPLATIN-INELIGIBLE PATIENTS; DNA METHYLATION; T-CELLS; PROSTATE-CANCER; SINGLE-ARM; BIOMARKERS; PEMBROLIZUMAB; ATEZOLIZUMAB; MULTICENTER; KEYNOTE-052; biomarker; bladder cancer; CD274; DNA methylation; immune checkpoint blockade; immunotherapy; metastatic urothelial carcinoma; PD-L1; promoter methylation | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 76231 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric